Alcon 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Alcon reported 3rd quarter 2026 sales of $2.7 billion, up 5% versus prior year, with year-to-date sales up 6%.
- Surgical sales increased 4% to $1.5 billion; implantables were down 2% to $422 million, consumables increased 6% to $789 million, and equipment increased 11% to $269 million.
- Vision Care sales increased 6% to $1.2 billion; contact lens sales rose 5% to $737 million and ocular health sales rose 8% to $500 million.
- Core gross margin was 65.7%, up 280 basis points year over year, and core operating income was $591 million, or 21.8% of sales, up 150 basis points.
- Core diluted earnings per share were $0.91, up 15% versus prior year. Alcon generated more than $1.3 billion of free cash flow in the first 9 months and returned $748 million to shareholders through dividends and share repurchases.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings. Welcome to the Alcon third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to Dan Cravens, VP and Global Head Investor Relations. Thank you, Dan. You may begin.
Welcome to Alcon's third quarter 2026 earnings conference call. Yesterday, we issued our press release, interim financial report, and earnings presentation. All of these documents are available on our website at investor.alcon.com. Joining me on today's call are David Endicott, our Chief Executive Officer, and Tim Stonesifer, our Chief Financial Officer. Before we begin, please note that our press release, presentation, and remarks today will include forward-looking statements, including statements regarding our future outlook. We undertake no obligation to update these statements as a result of new information or future events, except as required by law. Actual results may differ materially from those expressed or implied in these forward-looking statements. Please do not place undue reliance on them.
Important factors that could cause actual results to differ materially are included in our Form 20-F, earnings press release, and interim financial report, each of which is on file with the Securities and Exchange Commission and available on their website at sec.gov. We will also discuss certain non-IFRS financial measures. These measures may be calculated differently from and may not be comparable to similar measures used by other companies. They should be considered in addition to and not as a substitute for IFRS-prescribed performance measures. Reconciliation between our non-IFRS measures and the most directly comparable IFRS measures can be found in our earnings press release. For discussion purposes, our comments on growth rates are expressed in constant currency. In a moment, David will begin with highlights from the third quarter. After his remarks, Tim will walk through our financial performance in the quarter and outlook for the remainder of the year.
David will then return with closing comments before we open the line for Q&A. With that, I will turn the call over to our CEO, David Endicott.
Thanks, Dan, and good morning, everyone. In the third quarter, we grew sales 5%, bringing year-to-date growth to 6%. We remain on track to deliver on our full-year guidance of approximately 6% sales growth and double-digit core EPS growth, despite some specific areas of competitive pressure. As I reflect on the quarter, we saw good momentum across several parts of the portfolio. In surgical, equipment and consumables remained strong, particularly in the U.S., where demand for UNITY and Valeda continued to be robust, while implantables continued to grow in our international markets, but that growth was offset by competitive pressures in the U.S. In vision care, contact lenses and Ocular Health both delivered solid growth, driven by share gains in contact lenses, TRYPTYR, and Systane.
Now, Tim will take you through the detailed financials, so let me focus on what's driving the business and why we remain confident about the opportunities ahead. Underpinning our conviction that we can continue to grow faster than the market is a steady cadence of innovation, supported by clinical evidence that differentiates our products. At this fall's major congresses, we shared new data demonstrating the benefits of our latest technologies for surgeons, eye care professionals, and patients. At ESCRS, we presented new data reinforcing the unsurpassed near vision performance of PanOptix Pro and the surgical efficiency of UNITY VCS. At the Optometry and Ophthalmology annual meetings in the U.S., we shared new data showing Systane Pro delivered symptom relief clinically comparable to the prescription product MIEBO, with the accessibility and convenience of an over-the-counter option.
In addition, new research on TRYPTYR and dry eye showed clinically meaningful improvements in patients' ability to work and perform daily activities, with more than 70% reporting satisfaction with digital device use and end-of-day comfort. We also highlighted Valeda, the first and only FDA-approved treatment for early and intermediate dry AMD. We continue to build awareness among ophthalmologists and engage the broader eye care community to identify appropriate patients and broaden access to this important new treatment. Together, these data reinforce the differentiation of our newest products and support our efforts to translate that innovation into sustainable revenue growth. Now, we're seeing that innovation translate into commercial momentum in equipment, where UNITY VCS and CS, along with Valeda, drove double-digit growth.
In the U.S., UNITY continues to gain significant traction at some of the nation's most prominent academic medical centers, with placements secured in 40% of U.S. teaching hospitals in the past year alone. Importantly, when combined with our legacy platform, our equipment is now available in 98% of ophthalmology teaching programs, providing broad exposure to the next generation of surgeons. Turning to implantables, sales were down 2%, with IOLs down 1%, driven primarily by competitive launches in the U.S. premium IOL category and continued reimbursement challenges for dual procedures and glaucoma implants. In the U.S., competitive trialing and sampling of IOLs remain significant, and we expect that activity to continue through the early part of next year. At the same time, we are strengthening our competitive position with the next wave of innovation in our IOL portfolio, Vivity Pro.
Vivity Pro received FDA approval in the U.S. in early November, with CE mark expected soon. This lens was uniquely designed to improve near and intermediate vision without sacrificing distance or contrast. Our clinical data package at launch will include direct comparisons to competitive lenses. We began the U.S. KOL release last week and look forward to the full launch in January, with expansion into select European markets to follow during the first quarter. Additionally, TruPlus, our first entrant in the monofocal plus segment, is now broadly available in the U.S. and rolling out across Europe. Looking forward, our experience in Europe gives us confidence in how these competitive dynamics can evolve. Competitive launches there have now been in market for some time, and with PanOptix Pro as our response, we return to growth and are regaining PC-IOL share.
That provides an encouraging reference point as we prepare for the full U.S. and European launches of Vivity Pro in January. More broadly, we believe this next wave of innovation can strengthen our performance well beyond the near term. PanOptix Pro, Vivity Pro, and TruPlus are the beginning of a steady cadence of new IOL technologies that we believe will position us to drive sustainable above-market growth. Turning to contact lenses. We continue to gain share in the U.S. across both dailies and reusables, supported by the breadth of our WaterInnovations portfolio. That performance is an important example of our ability to win through differentiated innovation and commercial execution. The underlying market continues to benefit from premiumization as consumers move towards daily disposables and specialty lenses.
The TOTAL and PRECISION families give us premium and high-performance platforms, while innovations such as TOTAL30 Multifocal for Astigmatism expand our reach into higher-value specialty segments. We remain well-positioned to drive continued share and value growth. Finally, in Ocular Health, execution remains strong across both our prescription and consumer dry eye franchises. TRYPTYR continues to build momentum, reaching approximately 6% market share as of October. We've also recently initiated direct-to-consumer promotion to increase patient awareness and drive demand. We're making solid progress against our reimbursement objectives, with now more than two-thirds of commercial lives covered. On the consumer side, Systane delivered another quarter of double-digit growth, led by our multi-dose preservative-free formulations, including Systane Pro, as we continue to gain share in a fast-growing market. We're also continuing to broaden our consumer eye care portfolio.
Just a few weeks ago, the FDA approved BRYTLY, our new redness reliever eye drop. BRYTLY works in just one minute and provides up to 12 hours of redness reduction, lasting up to 50% longer than Lumify. We expect BRYTLY to be available at major retailers and online in the first quarter. Before turning to the market environment, let me highlight an important addition to our retina portfolio. We recently acquired Neurotech Pharmaceuticals, adding ENCELTO, the first and only FDA-approved treatment for macular telangiectasia type 2, or MacTel. This is a rare and progressive retinal disease that can cause irreversible central vision loss. ENCELTO is an encapsulated cell therapy that is intended for surgical intravitreal implantation. Neurotech is strategically compelling because it sits at the intersection of cell therapy, pharmaceuticals, and surgery, and it plays directly to Alcon's leadership in surgical retina.
There are approximately 25,000 diagnosed MacTel patients in the U.S. today, with an additional 2,000 to 3,000 newly diagnosed each year, and coverage is largely established. By combining Neurotech's differentiated technology and cell therapy capabilities with Alcon's commercial reach and retina relationships, we believe we can broaden access and build an important new long-term growth platform. We expect peak sales between $250 million to $400 million, with the ultimate trajectory largely dependent on how quickly patients are identified and brought into treatment. We are excited to welcome the Neurotech team and believe the acquisition strengthens both our retina franchise and the diversification of Alcon's future growth. Turning briefly to our efforts with ARYAN, we are pleased to report enrollment is complete in our pivotal phase III program, and we remain on track for a 2027 FDA submission and a 2028 FDA approval decision.
Before I close, let me share a few observations about the market environment. Let me start with contact lenses. Globally, the market remains healthy, growing in line with our assumptions at approximately 4%-5%, with roughly three points coming from price and two points from mix. The U.S. remains the strongest market, growing approximately 5%-6%. Growth outside the U.S. is more modest, particularly in Europe, where online channels and private label brands continue to put pressure on pricing, although mix remains positive. Across markets, the important trend is continued premiumization as consumers move toward daily disposables and specialty lenses. That shift supports positive mix and plays directly to the strength of our portfolio in these higher-valued categories. In cataract, procedure growth remains in line with our assumptions and below historical levels, reflecting capacity constraints in the U.S. and reimbursement and hospital economics internationally.
At the same time, premiumization remains a meaningful source of value growth, and we believe the strength and breadth of our premium IOL portfolio positions us well to capitalize on this trend. U.S. advanced technology IOL penetration reached 21.9%, up 160 basis points year-over-year, while international penetration increased 60 basis points to approximately 16%. Across our other eye care markets, underlying trends remain healthy and in line with our expectations. So when we put all that together, we estimate that our aggregate markets grew approximately 3% in the third quarter, at the low end of our assumptions underlying our guidance. Looking ahead, our base case assumes these trends broadly continue into next year, and our focus remains on execution, innovation, and premiumization across the business.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
